Targeted Delivery of RNAi Therapeutics With Endogenous and Exogenous Ligand-Based Mechanisms

Akin Akinc(Alnylam Pharmaceuticals (United States)), Martin A. Maier(Alnylam Pharmaceuticals (United States)), Eugenio Fava(Max Planck Institute of Molecular Cell Biology and Genetics), Marino Zerial(Max Planck Institute of Molecular Cell Biology and Genetics), June Qin(Alnylam Pharmaceuticals (United States)), Timothy Racie(Alnylam Pharmaceuticals (United States)), Antonin de Fougerolles(Alnylam Pharmaceuticals (United States)), K. N. Jayaprakash(Alnylam Pharmaceuticals (United States)), LiuLiang Qin(Alnylam Pharmaceuticals (United States)), J. Robert Dorkin(Alnylam Pharmaceuticals (United States)), Andrew Sprague(Alnylam Pharmaceuticals (United States)), Muthusamy Jayaraman(Forma Therapeutics (United States)), William Querbes(Alnylam Pharmaceuticals (United States)), Maria Frank-Kamenetsky(Alnylam Pharmaceuticals (United States)), Muthiah Manoharan(Alnylam Pharmaceuticals (United States)), Kallanthottathil G. Rajeev(Alnylam Pharmaceuticals (United States)), William Cantley(Alnylam Pharmaceuticals (United States)), James S. Butler(Alnylam Pharmaceuticals (United States)), Soma De(Alnylam Pharmaceuticals (United States)), Michael J. Hope(Acuitas Therapeutics (Canada)), Victor Koteliansky(Centre National de la Recherche Scientifique), Kevin Fitzgerald(Epsilon Systems (United States)), Anja Zeigerer(Heidelberg University), Mark A. Tracy(Alnylam Pharmaceuticals (United States)), Dinah W.Y. Sah(Port Washington Public Library)

Molecular Therapy

May 11, 2010

Cited by 1,236

|Biochimica et Biophysica Acta (BBA) - Biomembranes|1985|2.1k

|Nature Biotechnology|2010|1.8k

|Biochimica et Biophysica Acta (BBA) - Biomembranes|1986|1.7k

|Nature Nanotechnology|2019|1.6k

|Angewandte Chemie International Edition|2012|1.2k

Related Papers